Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a China-based pharmaceutical company, is poised to establish a joint venture (JV) with Germany’s Eckert & Ziegler Radiopharma Projekte UG. This strategic partnership aims to combine the expertise of both companies in the field of medical isotopes.
Investment and JV Formation
The joint venture will see DC Pharma invest EUR 20 million (USD 21.7 million) into the EZAG subsidiary Qi Kang Medical Technology (Changzhou) Co., Ltd. This investment, made through a capital increase, will result in DC Pharma holding a 50% stake in the JV. The partnership is designed to capitalize on the respective technologies and resource advantages of both companies.
Research, Development, and Marketing
The newly formed JV plans to focus on the research and development, manufacturing, and marketing of medical isotopes. By leveraging the combined strengths of Yantai Dongcheng and Eckert & Ziegler, the joint venture is well-positioned to make significant contributions to the medical isotopes market, enhancing the availability of these critical products for diagnostic and therapeutic applications.
